Approval for adding a new therapy vectibix (panitumumab) to intended use.  The device, as modified, will be marketed under the trade name dako egfr pharmdx kit and is indicated for: the egfr pharmdx assay is a qualitative immunohistochemical (ihc) kit system to identify epidermal growth factor receptor (egfr) expression in normal and neoplatic tissues routinely-fixed for histological evaluatin.  Egfr pharmdx specifically detects the egfr (her1) protein in egfr-expressing cells.  Egfr pharmdx is indicated as an aid in identifying colorectal cancer patients eligible for treatment with erbitux (cetuximab), or vectibix (panitumumab).